Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy

Emanuele Zucca(Università della Svizzera italiana), Catherine Thiéblemont(Université Paris Cité), Luca Mazzucchelli(Istituto Cantonale di Patologia), Stefan Hohaus, Peter Johnson(Cancer Research UK), Valter Torri(Istituti di Ricovero e Cura a Carattere Scientifico), Maurilio Ponzoni(San Raffaele University of Rome), Monica Bellei(University of Modena and Reggio Emilia), Réda Bouabdallah(Institut Paoli-Calmettes), Catherine Sebban(Ospedale San Giovanni Bellinzona), Elı́as Campo(Hospital Clínic de Barcelona), Corinne Haïoun(Assistance Publique – Hôpitaux de Paris), Pierre Zachée(Erasmus Hospital), Annarita Conconi(Ospedale degli Infermi), Armando López Guillermo(Ospedale San Giovanni Bellinzona), Caterina Stelitano(University of Reggio Calabria), Franco Cavalli(Institute of Social and Preventive Medicine), Franck Morschhauser(Hôpital Claude Huriez), Ruth Pettengell(University College Hospital), Maurizio Martelli(University of Milan), Andrew Jack(University of Alberta), Giovanni Martinelli(University of Bologna), Alessandra Tucci(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Gilles Salles(Memorial Sloan Kettering Cancer Center), Liliana Devizzi(Fondazione IRCCS Istituto Nazionale dei Tumori), André Bosly(University of Namur), Umberto Vitolo(Candiolo Cancer Institute), Graziella Pinotti(Medica (Italy)), Hervé Tilly(Centre Virchow-Villermé)

Journal of Clinical Oncology

March 29, 2017

Cited by 196

|New England Journal of Medicine|2002|3.9k

|New England Journal of Medicine|2018|2.3k

|Blood|2011|2k

|New England Journal of Medicine|2008|1.8k

|New England Journal of Medicine|2013|1.7k

Related Papers